Nuformix (LON:NFX) Issues Quarterly Earnings Results

Nuformix (LON:NFX) issued its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Nuformix Trading Down 6.7 %

NFX stock traded down GBX 0.01 ($0.00) during trading on Friday, reaching GBX 0.07 ($0.00). 37,799,703 shares of the stock traded hands, compared to its average volume of 86,003,250. The business’s 50 day moving average price is GBX 0.06 and its 200-day moving average price is GBX 0.10. The firm has a market capitalization of £573,517.00, a PE ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. Nuformix has a 52-week low of GBX 0.04 ($0.00) and a 52-week high of GBX 0.34 ($0.00).

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.